Algorithm of Evolution: OpenAI Unveils GPT-Rosalind for Drug Discovery

The healthcare industry is getting its own dedicated Foundation Model. On April 17, 2026, the official launch of `GPT-Rosalind` was confirmed—a specialized AI model from OpenAI tailored for life sciences.

This release perfectly explains the behind-the-scenes events of the past few days. It is now clear exactly what pharmaceutical giant Novo Nordisk signed a strategic partnership for on April 14. GPT-Rosalind is trained on massive datasets of biochemical data and is designed for drug discovery and translational medicine. The AI takes over the most expensive part of R&D—simulating protein structures and calculating drug compatibility—turning laboratories into data centers. Biology has definitively become a computational problem.

Source: OpenAI / Reuters